Trial of oral miltefosine for visceral leishmaniasis
Authors:
- Frank RosenkaimerFRFrank Rosenkaimer
- Manoj K MakhariaMMManoj K Makharia
- Ashish K GoyalAGAshish K Goyal
- Ashim K MandalAMAshim K Mandal
- Andreas VossAVAndreas Voss
- Peter HilgardPHPeter Hilgard
- Henry W MurrayHMHenry W Murray
Open Access
- 1 December 1998
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 352 (9143) , 1821-1823
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Response to Interferon‐γ plus Pentavalent Antimony in Indian Visceral LeishmaniasisThe Journal of Infectious Diseases, 1997
- The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma bruceiJournal of Antimicrobial Chemotherapy, 1996
- Short-Course Treatment of Visceral Leishmaniasis with Liposomal Amphotericin B (AmBisome)Clinical Infectious Diseases, 1996
- Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitroJournal of Cancer Research and Clinical Oncology, 1995
- Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azarThe Lancet, 1994
- Practical progress and new drugs for changing patterns of leishmaniasisParasitology Today, 1993
- Amphotericin versus pentamidine in antimony-unresponsive kala-azarThe Lancet, 1992
- A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumoursJournal of Cancer Research and Clinical Oncology, 1992
- Hexadecylphosphocholine induces interferon-γ secretion and expression of GM-CSF mRNA in human mononuclear cellsCellular Immunology, 1992
- Ketoconazole in visceral leishmaniasisThe Lancet, 1990